Download MendeleyThe First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.
Furet, P., Bordas, V., Le Douget, M., Salem, B., Mesrouze, Y., Imbach-Weese, P., Sellner, H., Voegtle, M., Soldermann, N., Chapeau, E., Wartmann, M., Scheufler, C., Fernandez, C., Kallen, J., Guagnano, V., Chene, P., Schmelzle, T.(2022) ChemMedChem 17: e202200303-e202200303
- PubMed: 35950546
- DOI: https://doi.org/10.1002/cmdc.202200303
- Primary Citation of Related Structures:
8A0U, 8A0V - PubMed Abstract:
Inhibition of the YAP-TEAD protein-protein interaction is an attractive therapeutic concept under intense investigation with the objective to treat cancers associated with a dysregulation of the Hippo pathway. However, owing to the very extended surface of interaction of the two proteins, the identification of small drug-like molecules able to efficiently prevent YAP from binding to TEAD by direct competition has been elusive so far. We disclose here the discovery of the first class of small molecules potently inhibiting the YAP-TEAD interaction by binding at one of the main interaction sites of YAP at the surface of TEAD. These inhibitors, providing a path forward to pharmacological intervention in the Hippo pathway, evolved from a weakly active virtual screening hit advanced to high potency by structure-based design.
Organizational Affiliation:
Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.
